Molbio Diagnostics IPO (10-12 August) Analysis

IPO Analysis | BSE and NSE Main Board | 100% Book Built Offer (Fresh Issue and Offer for Sale) | Regulation 6(1)

Based on Red Herring Prospectus dated August 3, 2026 | Point-of-Care Molecular Diagnostics (Truenat Platform) | Verna, South Goa

STATUS: LIVE RHP, ANCHOR BID AUGUST 7, BIDDING OPENS AUGUST 10 AND CLOSES AUGUST 12, 2026

Fresh Issue: up to Rs.2,000 Million | Offer for Sale: up to 9,166,000 Equity Shares by Promoters, a PE Fund and Other Selling Shareholders | Main Board Listing on BSE and NSE

Maker of the WHO-Endorsed 'Truenat' Point-of-Care Molecular Diagnostics Platform | RoNW of 14.55% (FY26) | Company States It Is Not Directly Comparable to Its Own Disclosed Peers

NOTABLE DISCLOSURE:

The Company and its subsidiary Bigtec Private Limited have a documented history of Companies Act non-compliance requiring adjudication or compounding proceedings, resulting in paid penalties totalling approximately Rs.83.08 million (Company: CSR shortfall Rs.32.00 million, MGT-14 delays Rs.0.89 million, private placement fund segregation violation Rs.8.00 million; Bigtec: CSR shortfall Rs.28.29 million, related-party loan approval lapse Rs.2.00 million, plus further penalties on associated entities). Separately, the Statutory Auditors' reports for FY24, FY25 and FY26 include CARO qualifications covering statutory dues delays, incomplete fixed asset verification, and 2 instances of fund misappropriation by external parties and a former employee (both since reported to police, with one arrest made). None of these required adjustment to the Restated Financial Information. See Section 6 for full detail.

Molbio Diagnostics Limited was originally incorporated as Molbio Diagnostics Private Limited on October 20, 2000, at Panaji, Goa, and converted to a public limited company on January 16, 2025. Its CIN is U33125GA2000PLC002909, with its registered and corporate office in Verna Industrial Area, South Goa. The Promoters are Sriram Natarajan, Dr. Chandrasekhar Bhaskaran Nair, Sangeetha Sriram, Shiva Sriram, Sowmya Sriram and Exxora Trading LLP.

The Company designs, develops and manufactures 'Truenat', a portable, battery-operated point-of-care molecular diagnostics platform using real-time PCR technology, developed with its R&D arm Bigtec Labs (now Bigtec Private Limited, a wholly owned subsidiary).

Truenat's TB diagnostic test is the only such platform developed by an Indian company and one of only two rapid molecular TB tests in the world endorsed by the World Health Organization, the Indian Council of Medical Research and the Foundation for Innovative New Diagnostics, with WHO having endorsed it as a complete replacement for smear microscopy.

The Company holds over 40 validated assays spanning TB, hepatitis, dengue, malaria and other diseases, and its Nipah virus test chip was the first in India to receive emergency use authorisation from the Drug Controller General of India. Truenat played a significant role in India's COVID-19 testing response and was among the first platforms approved by ICMR for that purpose. The Company operates manufacturing units in Goa (2 units) and Visakhapatnam.

Revenue from operations grew from Rs.8,365.61 million in Fiscal 2024 to Rs.14,456.87 million in Fiscal 2026, while PAT grew from Rs.835.42 million to Rs.1,641.40 million over the same period. Unlike several other companies in this report series, growth and margins moderated somewhat in the most recent year: EBITDA margin declined from 24.97% (FY25) to 22.56% (FY26), and RoE dipped from 16.20% to 15.59%, a trend discussed further in Section 4.

Key Basics

Particulars	Details
Document Type	Red Herring Prospectus (RHP) dated August 3, 2026. This is a live offer: Anchor Investor Bid Friday, August 7, 2026, Bid or Offer opens Monday, August 10, 2026 and closes Wednesday, August 12, 2026.
Issue Structure	100% Book Built Offer comprising a Fresh Issue of up to Rs.2,000.00 million and an Offer for Sale of up to 9,166,000 Equity Shares by a large group of Selling Shareholders. Face value Rs.1 per share, following a 1:10 sub-division and a subsequent 4:1 bonus issue in July 2025.
Face Value	Rs.1 per Equity Share.
Promoters and Selling Shareholders	Selling Shareholders include Promoters Exxora Trading LLP (up to 1,811,000 shares, WACA Rs.0.20) and Dr. Chandrasekhar Bhaskaran Nair (up to 1,221,000 shares, WACA Rs.6.90), alongside private equity investor India Business Excellence Fund III (up to 1,000,000 shares, WACA Rs.187.14, by far the highest WACA among disclosed sellers) and several other individual and corporate selling shareholders.
Eligibility Route	Regulation 6(1) of the SEBI ICDR Regulations, 2018, the standard main board profitability-based eligibility route.
Listing Exchange	Main board listing on both NSE and BSE Limited; BSE is the Designated Stock Exchange.
BRLMs	A 4-bank syndicate: Kotak Mahindra Capital Company Limited, IIFL Capital Services Limited, Jefferies India Private Limited and Motilal Oswal Investment Advisors Limited (the latter restricted to marketing only, given its affiliation with Selling Shareholder India Business Excellence Fund III).
Registrar	KFin Technologies Limited.
Bid or Offer Dates	Anchor Bid: Friday, August 7, 2026. Opens: Monday, August 10, 2026. Closes: Wednesday, August 12, 2026.
Listed Peers, One Line	4 listed peers in adjacent diagnostics and medical device segments (Poly Medicure, Dr. Lal PathLabs, Metropolis Healthcare, Vijaya Diagnostics), which the Company itself states are not directly comparable to its unique molecular diagnostics business.

This is a well known, internationally recognised diagnostics technology company with a genuinely differentiated product (the only WHO-endorsed Indian molecular TB diagnostic platform), and its 4-bank BRLM syndicate reflects that scale and profile.

The Offer for Sale is unusually broad, spanning Promoters, a private equity fund (India Business Excellence Fund III, exiting at a WACA more than 900 times higher than the lowest Promoter WACA disclosed) and several individual selling shareholders, giving this Offer a more complex ownership transition structure than most others in this series.

How Will the IPO Money Be Used?

Object	Estimated Amount (Rs. Million)	Substantiation
Capital expenditure for a new R&D facility and Center of Excellence (operated by wholly owned subsidiary Bigtec)	1,055.35	Total project cost of Rs.1,251.21 million; none yet deployed as of July 15, 2026. Scheduled deployment: Rs.264.74 million in FY27 and Rs.790.62 million in FY28.
Capital expenditure for plant, machinery and equipment at Goa Unit I, Goa Unit II and Visakhapatnam Unit	722.81	Total project cost of Rs.808.05 million; none yet deployed as of July 15, 2026.
General corporate purposes	[TBD]	No cap percentage located in the summary reviewed here; investors should confirm the exact cap in the full RHP.

This Issue's capital plan is entirely R&D and manufacturing capacity focused, directly supporting the Company's core competitive advantage: a dedicated R&D facility and Center of Excellence for its Bigtec subsidiary (the entity responsible for the underlying platform technology), plus incremental plant and machinery at its 3 existing manufacturing units.

As of this RHP, none of either capital expenditure Object had yet been deployed, so both carry standard execution timing risk over their FY27-FY28 deployment schedules. As with all RHPs at this stage, the fund requirements have not been independently appraised by any bank or financial institution, and the Net Proceeds and General Corporate Purposes figures remain undetermined until the Offer Price is fixed.

Financial Performance

P&L and Key Metrics (Rs. Million unless stated)

Particulars	FY 2026	FY 2025	FY 2024
Revenue from operations	14,456.87	10,204.18	8,365.61
Revenue from sale of devices	2,032.84	2,029.58	1,846.80
Revenue from sale of test kits	10,348.20	7,309.58	5,525.45
EBITDA	3,282.43	2,566.39	1,850.93
EBITDA margin (%)	22.56	24.97	22.02
EBITDA Pre-R&D margin (%)	28.57	31.64	29.13
Profit for the year	1,641.40	1,385.79	835.42
PAT margin (%)	11.28	13.48	9.94
Return on equity (%)	15.59	16.20	13.20
Return on capital employed (%)	17.55	20.98	15.80
Number of devices sold	2,524	2,180	2,011
Number of test kits sold (million)	17.56	12.24	8.80

Independently recomputed, revenue grew approximately 22.0% in FY25 and a further 41.7% in FY26, with continued growth in both devices sold (2,011 to 2,524) and test kits sold (8.80 million to 17.56 million), reconciling with the RHP's own disclosure. PAT grew from Rs.835.42 million in FY24 to Rs.1,641.40 million in FY26, nearly double.

However, unlike most other companies in this report series, profitability ratios moved in a less uniformly positive direction in the most recent year: EBITDA margin fell from 24.97% (FY25) to 22.56% (FY26), EBITDA Pre-R&D margin fell from 31.64% to 28.57%, and RoE dipped from 16.20% to 15.59% even as absolute revenue and profit both grew strongly.

This pattern is consistent with a company investing more heavily in R&D and scaling costs ahead of revenue in the most recent year, rather than a deterioration in the underlying business, but it is a genuine change in trend direction worth flagging, since most other reports in this series show margins improving in the most recent year rather than moderating.

How Does It Compare to Peers?

Company	Revenue (Rs. Million)	Diluted EPS (Rs.)	P/E (times)	RoNW (%)	NAV/Share (Rs.)
Molbio Diagnostics Limited	14,456.87	14.77	N/A (Price TBD)	14.55	101.51
Poly Medicure Limited	18,752.59	31.75	52.61	10.37	306.45
Dr. Lal PathLabs Limited	27,629.11	30.20	62.20	20.78	145.00
Metropolis Healthcare Limited	16,458.46	9.19	63.72	12.56	72.98
Vijaya Diagnostics Centre Limited	8,142.02	16.79	81.02	18.07	93.02

The Company itself is explicit that this peer comparison should be read with real caution: it states plainly that its business, in terms of key offerings, core business model and revenue type, varies considerably from the 4 listed peers disclosed (Poly Medicure, a disposable medical device manufacturer; and Dr. Lal PathLabs, Metropolis Healthcare and Vijaya Diagnostics Centre, all pathology diagnostic services providers), and that it believes it is not directly comparable to any of them, providing the comparison only for reference as its nearest available listed companies.

On RoNW, Molbio's 14.55% sits below 3 of the 4 peers (Dr. Lal PathLabs 20.78%, Vijaya Diagnostics 18.07%, Metropolis Healthcare 12.56% is close but slightly below) and above only Poly Medicure (10.37%).

Given the Company's own caution about comparability, this table should be treated as minimal context rather than a meaningful valuation anchor; Molbio's genuinely unique position (R&D and IP-driven molecular diagnostics manufacturing, versus disposable devices or lab services) means its economics may not track these peers closely.

Key Risks

l The Company and its wholly owned subsidiary Bigtec Private Limited have a documented history of Companies Act, 2013 non-compliance requiring adjudication or compounding proceedings before the Registrar of Companies and the Regional Director, Hyderabad, with penalties already paid totalling approximately Rs.83.08 million: CSR spending shortfalls at both the Company (Rs.32.00 million) and Bigtec (Rs.28.29 million) for Fiscals 2022 through 2024; a Section 42(6) violation for failing to segregate private placement application monies (Rs.8.00 million, Company); MGT-14 filing delays (Rs.0.89 million, Company); and a Section 185 lapse relating to loans Bigtec made to associate and subsidiary companies without prior shareholder approval (Rs.2.00 million, plus further penalties on the 3 recipient entities).

l The Statutory Auditors' reports on the Company's consolidated financial statements for FY24, FY25 and FY26 include CARO qualifications and, for FY24, an emphasis of matter paragraph. Disclosed matters include serious, large-volume delays in remittance of statutory dues (particularly provident fund) at subsidiary Bigtec across FY24 and FY25; 2 separate instances of fund misappropriation, Rs.4.43 million by external parties via fake purchase orders (Company, FY25, reported to cyber police) and Rs.6.09 million by a former Bigtec employee (FY24, employee dismissed and arrested); and incomplete physical verification and individual-asset-level record-keeping for property, plant and equipment, an exercise the Company expects to complete by March 2027. None of these required adjustment to the Restated Financial Information.

l The Company derives a meaningful portion of revenue from Indian central and state government tenders and from TB diagnostic test kits specifically, concentrating exposure to public procurement cycles and to the trajectory of a single, albeit globally significant, disease category.

l In Fiscal 2023, certain batches of Truenat TB and HPV test kits were exposed to excess humidity during manufacturing due to an air handling unit breakdown; the Company voluntarily recalled the affected lot as a precaution, and states this and other routine replacement instances over the last 3 fiscals did not have significant adverse impact, though the Company cannot assure similar instances will not recur.

l EBITDA margin, EBITDA Pre-R&D margin and RoE all declined in FY26 versus FY25 even as absolute revenue and profit grew, a change in trend direction from the margin-expansion pattern seen in most other companies in this report series, which the underlying data suggests is linked to increased R&D investment.

l The Offer for Sale includes a private equity investor, India Business Excellence Fund III, exiting at a Weighted Average Cost of Acquisition of Rs.187.14, and several other selling shareholders at varying cost bases; combined with the broad Promoter and related-party selling group, this is a more complex ownership transition than most other reports in this series.

l The Company has certain corporate records, including forms filed with the Registrar of Companies, that are not traceable.

l The Company has availed certain unsecured loans repayable on demand and has experienced past instances of delayed loan repayment (vehicle and term loan instalments delayed by 1 to 15 days across FY24 and FY25, since cured).

l The Company depends on a few suppliers for certain raw materials, relies on third parties for product transportation, and depends on distributors, particularly for government sector sales.

l The Company, Subsidiaries, Promoters and Directors are involved in certain legal and regulatory proceedings, and the Company carries contingent liabilities including bank guarantees (Rs.900.98 million) and disputed direct and indirect tax matters (Rs.461.48 million and Rs.322.37 million respectively).

l The Company recently invested in OptraScan INC and Chayagraphics (India) Private Limited and made an acquisition, introducing integration risk from these newer corporate actions.

l Majority of the Company's Directors are not directors of other listed companies, and the Company depends significantly on its Promoters, Senior Management and Key Managerial Personnel.

l The Company's Truenat platform for TB diagnosis is the only such platform developed by an Indian company and one of only 2 rapid molecular TB tests in the world endorsed by the WHO, ICMR and FIND, with WHO endorsing it as a complete replacement for smear microscopy, a genuinely differentiated, globally validated technology position built on 13 years of R&D.

l Both core volume metrics grew consistently across all 3 disclosed fiscal years: devices sold rose from 2,011 to 2,524 and test kits sold nearly doubled from 8.80 million to 17.56 million, indicating expanding real-world adoption rather than revenue growth from pricing alone.

l PAT nearly doubled from Rs.835.42 million in FY24 to Rs.1,641.40 million in FY26, and the Company's margin moderation in FY26 appears linked to increased R&D investment (a core strategic priority reflected in this Offer's capital expenditure Objects) rather than deteriorating unit economics.

l The Company responded to every disclosed compliance and fraud matter with formal, documented remediation: adjudication and compounding applications filed proactively with regulators, all resulting penalties paid in full, cyber and police complaints filed for both misappropriation incidents (with one arrest secured), and a systematic asset-verification exercise targeted for completion by March 2027.

l The Company holds an unusually broad and validated assay portfolio (over 40 assays spanning TB, hepatitis, dengue, malaria and other diseases) on a single decentralised, battery-operated platform, and was among the first approved by ICMR during the COVID-19 pandemic and the first in India to receive emergency use authorisation for Nipah virus diagnosis.

l The Company's own capital expenditure Objects for this Offer are precisely itemised by project (a dedicated R&D Center of Excellence for Bigtec, plus plant and machinery at each of its 3 named manufacturing units), giving investors clear visibility into how growth capital will be deployed.

Disclaimer

The content on this website is for informational and educational purposes only and should not be construed as investment advice, a recommendation, or a solicitation to buy or sell any security, mutual fund, or financial instrument. Equity Research India is not a SEBI-registered investment advisor or research analyst, and nothing on this site constitutes personalized financial advice.

Mutual fund investments are subject to market risks. Please read all scheme-related documents carefully before investing. Past performance is not indicative of future returns. NAV, returns, rankings, and other data may change and may not reflect the most current information at the time of reading.

Readers should conduct their own due diligence and consult a SEBI-registered financial advisor before making any investment decisions. Equity Research India and its authors accept no liability for any loss or damage arising from the use of this content.